- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05198089 | Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients with Cancer | completed | Phase 1 | 52 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 |
| Sep 27, 2024 |
| clinicaltrials |
| NCT05773937 | A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors | recruiting | Phase 1 | 40 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592417 | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 140 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03320330 | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Children's Oncology GroupNETWORK | 1 | Jul 15, 2024 | clinicaltrials |
| NCT04532372 | Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy | completed | Phase 1 / Phase 2 | 2 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | completed | Phase 1 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03525925 | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | completed | Phase 1 | 16 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06304818 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. | not yet recruiting | Phase 1 / Phase 2 | 515 | Sinocelltech Ltd.INDUSTRY | 0 | Mar 15, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04165590 | Plasmodium Immunotherapy for Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05930457 | Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | completed | Phase 1 | 15 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT02808650 | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05814835 | First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | completed | Phase 1 | 14 | Chinese PLA General HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06166472 | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor | unknown | Phase 1 | 72 | AkesoINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03831295 | SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies | completed | Phase 1 | 12 | Ronald LevyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03784677 | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04168320 | SBRT-based PArtial Tumor Irradiation of HYpoxic Segment(SBRT-PATHY) | terminated | Phase 1 | 30 | Klinikum Klagenfurt am WörtherseeOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT02780804 | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT03017833 | Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT01376505 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | completed | Phase 1 | 65 | Robert WesolowskiOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02317874 | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04729725 | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05886374 | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 81 | HutchmedINDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05396339 | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 120 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05911984 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 27 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03884517 | Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer | terminated | Phase 1 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 28, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04571892 | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 58 | Shanghai East HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02754141 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 235 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 5, 2023 | clinicaltrials |
| NCT05539157 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | unknown | Phase 1 | 1 | Immorna Biotherapeutics, Inc.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03756818 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT01023737 | Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | completed | Phase 1 | 72 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02959905 | Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) | completed | Phase 1 | 11 | BGI, ChinaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 8, 2024source: clinicaltrials